Abivax SA Sponsored ADR $ABVX Stake Lifted by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. increased its holdings in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) by 3,436.1% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 168,705 shares of the company’s stock after acquiring an additional 163,934 shares during the period. Jefferies Financial Group Inc.’s holdings in Abivax were worth $16,705,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the business. Two Seas Capital LP acquired a new stake in Abivax in the 3rd quarter valued at $66,996,000. Eversept Partners LP boosted its stake in shares of Abivax by 42.0% during the 1st quarter. Eversept Partners LP now owns 934,423 shares of the company’s stock worth $104,048,000 after buying an additional 276,589 shares during the last quarter. Bank of America Corp DE boosted its stake in shares of Abivax by 40.9% during the 1st quarter. Bank of America Corp DE now owns 735,729 shares of the company’s stock worth $81,923,000 after buying an additional 213,440 shares during the last quarter. Janus Henderson Group PLC grew its holdings in shares of Abivax by 31.6% in the 1st quarter. Janus Henderson Group PLC now owns 878,829 shares of the company’s stock valued at $98,007,000 after acquiring an additional 211,068 shares in the last quarter. Finally, CenterBook Partners LP grew its holdings in shares of Abivax by 321.4% in the 3rd quarter. CenterBook Partners LP now owns 142,496 shares of the company’s stock valued at $14,110,000 after acquiring an additional 108,685 shares in the last quarter. Institutional investors own 47.91% of the company’s stock.

Abivax Stock Performance

Shares of NASDAQ:ABVX opened at $91.44 on Thursday. Abivax SA Sponsored ADR has a 52-week low of $69.81 and a 52-week high of $148.83. The company has a market capitalization of $8.01 billion, a P/E ratio of -15.09 and a beta of 1.36. The company has a 50-day simple moving average of $95.79 and a 200 day simple moving average of $112.84.

Abivax (NASDAQ:ABVX) last posted its quarterly earnings results on Monday, September 21st. The company reported ($1.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.79). The company had revenue of $1.37 million during the quarter, compared to analyst estimates of $0.80 million. As a group, equities analysts forecast that Abivax SA Sponsored ADR will post -4.14 earnings per share for the current year.

Analyst Ratings Changes

ABVX has been the topic of a number of recent research reports. Morgan Stanley reaffirmed an “overweight” rating and issued a $180.00 target price on shares of Abivax in a research report on Friday, July 24th. Wall Street Zen cut Abivax from a “hold” rating to a “sell” rating in a research report on Saturday, September 26th. Guggenheim reissued a “buy” rating and set a $175.00 price target on shares of Abivax in a research report on Tuesday, October 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Abivax in a research note on Thursday, October 15th. Finally, Barclays reaffirmed an “overweight” rating and set a $148.00 price target on shares of Abivax in a research report on Tuesday, September 22nd. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $155.00.

Abivax Company Profile

Abivax is a clinical-stage biopharmaceutical company headquartered in Paris, France. It develops treatments for chronic inflammatory diseases, with a focus on therapies that regulate the body’s immune response. The company’s lead candidate, obefazimod (formerly known as ABX464), is an oral small molecule being studied for ulcerative colitis and other inflammatory conditions. It is designed to increase production of miR-124, a molecule involved in regulating inflammation. Founded in 2013, Abivax conducts clinical development internationally.